
Cassel Salpeter & Co.’s Q3 healthcare update points to disrupted NIH grant processing, FDA attrition, and tariffs as pressures on drug development and early-stage financing.
A Revolution in Physician Targeting: In-source analytics-driven intelligence to go beyond decile-based targeting - SAS Whitepaper






